The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Studies Highlight Risk of Damage from Lupus Treatments

Studies Highlight Risk of Damage from Lupus Treatments

April 20, 2017 • By Mary Beth Nierengarten

  • Tweet
  • Email
Print-Friendly Version / Save PDF
Marcos Mesa Sam Wordley/shutterstock.com

Marcos Mesa Sam Wordley/shutterstock.com

WASHINGTON, D.C.—Conference goers who braved the final day of the 2016 ACR/ARHP Annual Meeting were awarded for their stamina by learning about issues relating to the damage caused by systemic lupus erythematosus (SLE) during the session Systemic Lupus Erythematosus—Clinical Aspects and Treatment V: Damage and Morbidity.

You Might Also Like
  • Rheumatology Research Abstracts Highlight Treatment for Hand OA, Risk of Depression in Lupus and More
  • Biomarkers, Genetic Clues to Higher Cardiovascular Disease Risk in Patients with Lupus
  • Bipolar Disorder, Nailfold Capillaroscopy Score, Urban Location Among Risk Factors for Developing Lupus
Explore This Issue
April 2017
Also By This Author
  • Evolutionary Medicine Provides Insight into the Chronic Inflammatory State Note Rheumatologists at the 2013 ACR/ARHP Annual Meeting

Minimizing Damage: Early Use of GC-Sparing Strategies

Jayne Little, MSc, National Institute for Health Research, Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospital NHS Foundation Trust, Manchester, U.K., presented the results of a study that showed the importance of using glucocorticoid (GC)-sparing strategies early to minimize the risk of damage in patients with SLE.1

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Using data from 1,700 SLE patients in the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort, Ms. Little reported on the cumulative incidence of total and GC-related damage.

The SLICC cohort recruited 1,848 patients between 2000 and 2011, all of whom had developed four or more 1997 ACR criteria for SLE within 15 months prior to recruitment. This current study included 1,700 patients from the cohort who had a minimum of one follow-up visit (in addition to their enrollment visit) and a SLICC Damage Index (SDI) score recorded at least once. Most patients were female (88.6%), white (50%) and had an average age of 33 years at baseline. Most patients (70%) were on an oral GC at enrollment, but oral GC use declined with increasing disease duration. However, 90.5% of patients received oral GCs at some time during the study. Parenteral GC use was uncommon prior to enrollment (13.8%), as well as during the study period (approximately 4.3%).

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

To assess the accumulation of damage, the investigators explored the trend in total SDI scores and cumulative incidence of SDI damage items over time. The individual damage items had previously been grouped (through a consensus exercise performed among SLICC) into those items “definitely,” “probably” or “not” associated with the use of GCs.

The study found that the total SDI score increased over time in a linear fashion. At enrollment, 23% of patients had some damage (SDI >0). At 10 years, this percentage increased to 54% (with a mean SDI of 2).

When looking at individual items, the study found that the most common damage in early disease (within two years of diagnosis) was alopecia, proteinuria and cognitive impairment, occurring in about 3% of patients, followed by diabetes and cataracts, occurring in about 2% of patients. Of these, diabetes and cataracts, and probably cognitive impairment, were linked to the usage of GCs. At 10 years, the cumulative incidence of alopecia and cataracts was 10% of the population.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

‘These data on secular trends & disparities call to action the need to develop targeted research & public health programs to identify the modifiable risk factors in order to promote health equity among patients of all backgrounds with SLE.’ —Dr. Ram R. Singh

When looking at musculoskeletal items, the study found that although the cumulative incidence of avascular necrosis was relatively low at two years, by 10 years it was within the top five items, with a cumulative incidence of 6.8%. Other musculoskeletal items that were relatively common included deforming erosive arthritis and GC-related damage, including osteoporotic fracture and muscle atrophy/weakness, with cumulative incidences of 2.6% and 3.6%, respectively, at 10 years.

Pages: 1 2 3 4 | Single Page

Filed Under: Conditions, Meeting Reports, SLE (Lupus) Tagged With: 2016 ACR/ARHP Annual Meeting, American College of Rheumatology, damage, glucocorticoid, Lupus, morbidity, mortality, patient care, Research, rheumatology, SLE, therapy, TreatmentIssue: April 2017

You Might Also Like:
  • Rheumatology Research Abstracts Highlight Treatment for Hand OA, Risk of Depression in Lupus and More
  • Biomarkers, Genetic Clues to Higher Cardiovascular Disease Risk in Patients with Lupus
  • Bipolar Disorder, Nailfold Capillaroscopy Score, Urban Location Among Risk Factors for Developing Lupus
  • Mortality Trends in Lupus Nephritis

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.